Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1452.780
- -1.619-0.11%
Trading Feb 25 09:50 ET
1459.686High1443.392Low
1454.226Open1454.399Pre Close2.03MVolume1RiseLossP/E (Static)69.64MTurnover--Flatline0.16%Turnover Ratio173.89BMarket Cap9Fall171.61BFloat Cap
Constituent Stocks: 10Top Rising: VRTX+0.21%
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Friday, 21st February at 7:30 am
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions
bluebird's Board of Directors determined this transaction is in the best interest of stockholders following a comprehensive review of strategic alternatives
...
Can bluebird bio Hit $600M Sales Target? What the $9.84 Per Share Buyout Really Means
Bluebird bio Announces Definitive Agreement to Be Acquired by Carlyle and SK Capital! Bluebird bio Inc - Stockholders to Receive $3.00 per Share in Cash
Bluebird Bio: Contingent Value Right of $6.84/Share Payable Upon Achievement of Sales Milestone
The transaction is expected to close in the first half of 2025, subject to the tender of a majority of the outstandin...
What's Fueling HIMS' Rally?
HIMS surged 17.5% on Wednesday following the announcement of an acquisition, reaching an intraday high of nearly 25% and hitting a record $72.
Hims & Hers disclosed it acquired Sigmund NJ LLC, also known as Trybe La...
No comment yet